Bernard A. Fox: UbiVac is excited to have the world’s 1st immunotherapy that targets cancer’s Dark Matter
Bernard A. Fox, Co-Founder, President, and CEO of UbiVac, shared on LinkedIn:
“Ryan Witt thanks for the shout out! UbiVac is excited to have the world’s 1st immunotherapy that targets cancer’s Dark Matter as well as >300 TAAs, and wraps it all up in an off-the-shelf microparticle packed with immune stimulants. We believe it is currently the best immunotherapy treatment strategy for HPV+ or HPV- recurrent or metastatic head and neck squamous cell cancer (HNSCC). While only 18 pts evaluable, it has improved response rates in 1st line or post checkpoint failure.
I have been involved in translational cancer immunotherapy trials since joining Dr. Steven A Rosenberg’s lab in Bldg 10 at the National Cancer Institute (NCI) in 1985. But it’s not me. This is a team effort. Besides UbiVac, my colleagues at Earle A. Chiles Research Institute, Providence Cancer Institute and importantly Incyte – who are funding the trial, made this possible.
This includes Drs. Rom Leidner, Carlo Bifulco, R. Bryan Bell, Walter Urba Shawn Jensen, Christopher Paustian, Venkatesh Rajamanickam, William Redmond, Yoshinobu (Yoshi) Koguchi, Susan Snodgrass, John Janik, Lothar H Finke, Jon Wigginton, Sung Poblete, Hilton Traci, Nancy Lime, Brian Piening, Ryan Meng, Erich Merrill, Steve Buhaly, Bernie Fox / plus many others who have helped us along the way Alan Braynin, Nancy Hurley, David Jablons, James Mule’, Samir Khleif, Pamela Klein, Cassian Yee, John Connolly, Alan Korman, Nils Lonberg, Raj Puri, Asthika Goonewardene, Sam Fazeli
FYI: UbiVac’s DPV-001 was designed as treatment for most solid cancers, including breast cancer, prostate cancer gastric cancer, colon cancer, ovarian cancer, lung cancer, pancreatic cancer, colon cancer and glioblastoma – plus more. We are looking for partners to help us expand our reach. “
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023